Developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy

开发定量超声乳腺扫描仪来识别乳腺癌对化疗的早期反应

• 批准号: 10686414
• 负责人: Gregory Jan Czarnota
• 金额: $ 49.1万
• 依托单位: UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-18 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686414
• 关键词: 3-Dimensional; Address; Adjuvant Chemotherapy; Anatomy; Breast Cancer Patient; Breast Cancer therapy; Clinical; Clinical Data; Contrast Media; Data; Detection; Devices; Disease-Free Survival; Early identification; Early treatment; Feedback; Frequencies; Health Sciences; Human; Image; In complete remission; Institution; Ionizing radiation; Knowledge; Magnetic Resonance Imaging; Malignant Neoplasms; Mammary Ultrasonography; Mammography; Marketing; Marriage; Measures; Monitor; Neoadjuvant Therapy; Operative Surgical Procedures; Outcome; Pathologic; Patient-Focused Outcomes; Patients; Performance; Physical assessment; Process; Prognosis; Radiation; Resolution; Savings; Scanning; Signal Transduction; Speed; Techniques; Technology; Testing; Time; Tissues; Translating; attenuation; breast imaging; breast scanner; cancer therapy; chemotherapy; cohort; cost; data acquisition; improved; individual patient; malignant breast neoplasm; patient response; personalized medicine; quantitative imaging; quantitative ultrasound; response; sound; success; tomography; transmission process; treatment response; tumor; ultrasound

PROJECT SUMMARY In this proposal, we will develop new images modes on the QT Ultrasound® tomographic breast scanner and demonstrate that the scanner with the new image modes can accurately identify the response of breast cancer patients to chemotherapy. A poorly met clinical need in breast cancer therapy is providing inexpensive and accurate ways to identify patient responses to chemotherapy early during the course of therapy. For many breast cancers, lack of patient response to initial therapy is predictive of poor outcome, whereas pathological complete response strongly correlates with extended survival. Conventional clinical surrogates of response based on anatomical information such as physical assessments, mammography and standard clinical ultrasound provide poor early assessments of treatment response. We demonstrated that quantitative analysis of ultrasound backscatter (QUSB) using conventional hand-held clinical scanners can provide promising metrics of response of breast cancer to neoadjuvant chemotherapy (NAC/AC) within one week of therapy initiation. These QUSB results would benefit greatly from improved volumetric accuracy that conventional scanning platforms do not support, such as transmission and attenuation losses in the signals. We propose to solve these issues by integrating QUSB with the newly available QT Ultrasound® breast scanner. This FDA cleared and marketed scanner delivers 3D quantitative images of the breast including sound speed, (SOS) reflectivity (R) and attenuation (A) values. The QT Ultrasound® breast scanner corrects refractive and interface attenuation losses. It also provides compounding of multiple angles of view that will further improve QUSB variance. The scanner’s parameters of SOS, R, A, and mm3 volume measuring accuracy provide supplementary quantitative features likely to contribute robustness to early identification of response. We believe that the QUSB+QT Ultrasound® breast scanner can identify response at a level better than MRI. Even if response identification is only comparable, QUSB+QT Ultrasound® savings in costs, ease of use, noninvasive native contrast, and patient acceptance would markedly simplify management of breast cancer therapy and deliver considerable practical advantage and increased accuracy. Therefore, our scientific premise is that QUSB integrated on the QT Ultrasound® breast scanner will provide improved identification of early response of breast cancer patients to NAC. Our preliminary data demonstrate that QUSB techniques can identify nonresponders and predict patient outcomes. Our preliminary results also demonstrate that QUSB techniques integrate with the QT Ultrasound® platform and benefit from improved QUSB bias and variance. Therefore, the proposal consists of three aims. The first specific aim is to implement, test and validate QUSB techniques on the latest QT Ultrasound® breast scanner for clinical data acquisition. The second specific aim is to quantify the capacity of QUSB+QT Ultrasound® quantitative data to identify nonresponders. The final specific aim is to quantify the capacity of QUSB+QT Ultrasound® quantitative data to predict patient outcomes.

项目摘要 在此提案中，我们将在QTUltrasound®层析成像乳房扫描仪和 证明具有新图像模式的扫描仪可以准确识别乳腺癌的反应 接受化学疗法的患者。在乳腺癌治疗中满足临床需求不足，可提供便宜的 在治疗过程中早期鉴定患者对化疗的反应的准确方法。对于许多乳房 癌症，缺乏对初始治疗的患者反应可预测结果不佳，而病理完整 反应与扩展生存率密切相关。基于常规的临床反应替代 解剖信息，例如物理评估，乳房X线摄影和标准临床超声提供 对治疗反应的早期评估不良。我们证明了超声的定量分析 使用常规手持临床扫描仪的反向散射（QUSB）可以提供响应的有望指标 在治疗计划的一周内，乳腺癌到新辅助化疗（NAC/AC）。这些QUSB 从传统扫描平台没有的提高的体积准确性中，结果将大大受益 支持，例如信号中的传输和衰减损失。 我们建议通过将QUSB与新的QTUltrasound®乳房集成来解决这些问题 扫描器。该FDA清除和销售的扫描仪可提供乳房的3D定量图像，包括声音 速度，（SOS）反射率（R）和衰减（a）值。 QTUltrasound®乳房扫描仪校正折射率 和界面衰减损失。它还提供了多个视角的复合，这将进一步改善 QUSB方差。 SOS，R，A和MM3体积测量精度的扫描仪参数提供 补充定量特征可能有助于早期识别反应的鲁棒性。 我们认为，QUSB+QTUltrasound®乳腺扫描仪可以比MRI更好地识别响应。 即使响应识别仅可比，QUSB+QTultrasound®节省成本，易用性， 无创的本地对比和患者的接受度将显着简化乳腺癌的治疗 治疗并带来可观的实际优势和提高准确性。因此，我们的科学前提 是否集成在QTUltrasound®乳房扫描仪上的QUSB可以改善早期的识别 乳腺癌患者对NAC的反应。我们的初步数据表明QUSB技术可以识别 无反应并预测患者的预后。我们的初步结果也证明了QUSB技术 与QTUltrasound®平台集成在一起，并受益于改善QUSB偏差和差异。因此， 提案由三个目标组成。第一个具体目的是实施，测试和验证QUSB技术 最新的QTUltrasound®乳房扫描仪用于临床数据获取。第二个具体目的是量化 QUSB+QTultrasound®定量数据的容量以识别未响应者。最终的具体目的是 量化QUSB+QTUltrasound®定量数据的能力以预测患者的预后。